390 – Immune-Related AEs After Low-Dose, Finite-Duration Budigalimab ± Trosunilimab in PWH
Background Budigalimab and trosunilimab, recombinant IgG1 monoclonal antibodies that bind cell-surface PD-1 receptor and α4β7 integrin, respectively, are being studied as a potential strategy for immune-mediated control of HIV. In oncology indications, higher doses of budigalimab (250-500mg) are associated with immune-related adverse events (irAEs) in ~40% of patients (5% Grade [Gr]≥3). However, the safety profile of…